Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
E-BookPDF2 - DRM Adobe / Adobe Ebook ReaderE-Book
536 Seiten
Englisch
John Wiley & Sonserschienen am14.02.20181. Auflage
Practical guidance based on expert experience and evidence for developing management strategies for vitiligo 

This complete guide to vitiligo provides a full appraisal of strategy for the treatment of this autoimmune disease that affects 1-2% of the world's population. It addresses all aspects of vitiligo, covering the science, medical and surgical therapies, and the psychological evaluations and approaches based on the proper understanding of the causes and classification of a particular case.

Management of vitiligo is challenging and requires a multipronged approach. Vitiligo: Medical and Surgical Management is a comprehensive, timely, state-of-the-art resource that will help those involved with affected patients better understand and treat this disease, which takes its toll on the mental wellness of those afflicted by it. It takes an evidenced-based approach to the disease's treatment; provides an overview of the surgical management; covers tissue and cellular grafting; and more. 
Thoroughly guides those involved in the clinical aspects of vitiligo
Aids diagnosis and classification of severity
Balances evidence and experience
Compiled by world-leading expert editors

Comprehensive in nature, Vitiligo: Medical and Surgical Management contains a strong practical element, and is a welcome go-to source for practicing dermatologists and those training to become a dermatologist.



About the Editors
Somesh Gupta, MD, DNB, MNAMS, Professor, Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India
Mats J. Olsson, MD, PhD, CEO, ParkCell AB and President, International Vitiligo Center, Uppsala, Sweden
Davinder Parsad, MD, Professor, Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
Henry W. Lim, MD, Chair Emeritus, Department of Dermatology and Senior Vice President for Academic Affairs, Henry Ford Health System. Past President, American Academy of Dermatology, Detroit, USA
Nanja van Geel, MD, PhD, Professor, Department of Dermatology, Ghent University Hospital, Ghent, Belgium
Amit G. Pandya, MD, Professor, Department of Dermatology, University of Texas, Southwestern Medical Center, Dallas, USAmehr
Verfügbare Formate
BuchGebunden
EUR249,50
E-BookPDF2 - DRM Adobe / Adobe Ebook ReaderE-Book
EUR203,99
E-BookEPUB2 - DRM Adobe / EPUBE-Book
EUR203,99

Produkt

KlappentextPractical guidance based on expert experience and evidence for developing management strategies for vitiligo 

This complete guide to vitiligo provides a full appraisal of strategy for the treatment of this autoimmune disease that affects 1-2% of the world's population. It addresses all aspects of vitiligo, covering the science, medical and surgical therapies, and the psychological evaluations and approaches based on the proper understanding of the causes and classification of a particular case.

Management of vitiligo is challenging and requires a multipronged approach. Vitiligo: Medical and Surgical Management is a comprehensive, timely, state-of-the-art resource that will help those involved with affected patients better understand and treat this disease, which takes its toll on the mental wellness of those afflicted by it. It takes an evidenced-based approach to the disease's treatment; provides an overview of the surgical management; covers tissue and cellular grafting; and more. 
Thoroughly guides those involved in the clinical aspects of vitiligo
Aids diagnosis and classification of severity
Balances evidence and experience
Compiled by world-leading expert editors

Comprehensive in nature, Vitiligo: Medical and Surgical Management contains a strong practical element, and is a welcome go-to source for practicing dermatologists and those training to become a dermatologist.



About the Editors
Somesh Gupta, MD, DNB, MNAMS, Professor, Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India
Mats J. Olsson, MD, PhD, CEO, ParkCell AB and President, International Vitiligo Center, Uppsala, Sweden
Davinder Parsad, MD, Professor, Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
Henry W. Lim, MD, Chair Emeritus, Department of Dermatology and Senior Vice President for Academic Affairs, Henry Ford Health System. Past President, American Academy of Dermatology, Detroit, USA
Nanja van Geel, MD, PhD, Professor, Department of Dermatology, Ghent University Hospital, Ghent, Belgium
Amit G. Pandya, MD, Professor, Department of Dermatology, University of Texas, Southwestern Medical Center, Dallas, USA
Details
Weitere ISBN/GTIN9781118937389
ProduktartE-Book
EinbandartE-Book
FormatPDF
FormatFormat mit automatischem Seitenumbruch (reflowable)
Erscheinungsjahr2018
Erscheinungsdatum14.02.2018
Auflage1. Auflage
Seiten536 Seiten
SpracheEnglisch
Dateigrösse54449 Kbytes
Artikel-Nr.3375878
Rubriken
Genre9201

Inhalt/Kritik

Inhaltsverzeichnis
1;Title Page;5
2;Copyright Page;6
3;Contents;9
4;List of Contributors;15
5;Foreword;21
6;Preface;23
7;About the Companion Website;25
8;Section 1 Basic Science;27
8.1;Chapter 1 Introduction;29
8.1.1;Vitiligo is Clinically Visible as Cutaneous Depigmentations;29
8.1.2;Vitiligo is a Disease with an Important Psychosocial Impact;29
8.1.3;The Search for New Vitiligo Therapies is on;31
8.1.4;Surgical Management of Vitiligo;31
8.1.5;The Hair Follicle is Considered an Immunologically Privileged Site;33
8.1.6;Stability of the Disease and Repigmentation Achieved by Treatment;33
8.1.7;References;33
8.2;Chapter 2 Melanocyte and Melanogenesis: Applied Anatomy and Physiology;35
8.2.1;The Pigmentary System;35
8.2.2;Embryological Development;36
8.2.3;Melanogenesis;36
8.2.4;Melanocortin 1 Receptor (MC1R) Signaling;37
8.2.5;KIT Signaling Pathway;37
8.2.6;The Melanosome;37
8.2.7;References;38
8.3;Chapter 3 Epidemiology of Vitiligo;41
8.3.1;Introduction;41
8.3.2;International Prevalence of Vitiligo;41
8.3.3;Gender Equivalency of Vitiligo;42
8.3.4;Age of Presentation of Vitiligo;42
8.3.5;Vitiligo and Associated Comorbidities;42
8.3.6;Inheritance Patterns;43
8.3.7;Conclusions;43
8.3.8;References;43
8.4;Chapter 4 Pathogenesis of Vitiligo;45
8.4.1;Introduction;45
8.4.2;Vitiligo Pathogenesis;45
8.4.3;Relevance to Treatment Approach;48
8.4.4;Medical Treatment;48
8.4.5;Surgical Treatment;50
8.4.6;Summary;50
8.4.7;References;50
8.5;Chapter 5 Understanding the Mechanisms of Repigmentation in Vitiligo;53
8.5.1;Introduction;53
8.5.2;Mechanisms of Repigmentation: Medically Induced;54
8.5.3;Mechanisms of Repigmentation: Surgically Induced;56
8.5.4;References;57
9;Section 2 Clinical Science;59
9.1;Chapter 6 Classification and Clinical Features of Vitiligo;61
9.1.1;Introduction;61
9.1.2;Classification of Vitiligo;61
9.1.3;Clinical Characteristics of Vitiligo/Non?segmental Vitiligo;63
9.1.4;Clinical Features of Segmental Vitiligo;65
9.1.5;Undetermined/Unclassified Vitiligo;69
9.1.6;Other Types or Rare Variants;69
9.1.7;Acknowledgments;71
9.1.8;References;71
9.2;Chapter 7 Outcome Measures for Vitiligo;75
9.2.1;Introduction;75
9.2.2;Repigmentation;76
9.2.3;3-D Image Analysis;79
9.2.4;Disease Activity;80
9.2.5;Quality of Life Measures;81
9.2.6;Conclusions;83
9.2.7;References;84
9.3;Chapter 8 Evaluation and Treatment of the Psychosocial Burden of Vitiligo;87
9.3.1;Introduction;87
9.3.2;Why Assess the Psychological Impact of Vitiligo in Patients?;87
9.3.3;Psychosocial Impact of Vitiligo;87
9.3.4;Patient Evaluation and Expectation Assessment;88
9.3.5;Management of the Psychosocial Burden of Vitiligo;89
9.3.6;Other Interventions;90
9.3.7;Support Groups;91
9.3.8;References;91
9.4;Chapter 9 Patient Support, Education, and Compliance;95
9.4.1;Introduction;95
9.4.2;Psychosocial Morbidity in Vitiligo;95
9.4.3;Psychosocial Interventions in Vitiligo;96
9.4.4;Educational Resources for Patients with Vitiligo;97
9.4.5;Psychological Effects of Vitiligo;98
9.4.6;Communication - Vital for Better Perception, Commitment, and Outcomes;99
9.4.7;Strategies to Improve Compliance;99
9.4.8;Role of Realistic Expectations;99
9.4.9;Conclusions;100
9.4.10;References;100
9.5;Chapter 10 Goals of Vitiligo Treatment, and Evidence-Based Practice Guidelines for Medical and Surgical Management;103
9.5.1;Introduction;103
9.5.2;Example - Psoriasis Treatment Goals;103
9.5.3;Goals of Vitiligo Treatment from the Patient s Perspective;104
9.5.4;Goals of Vitiligo Treatment from the Physician s Perspective;104
9.5.5;Conclusions;105
9.5.6;References;105
9.6;Chapter 11 The Concept of Stability of Vitiligo and Stabilization Therapies;107
9.6.1;Introduction;107
9.6.2;Monitoring Stability;107
9.6.3;Clinical Features and Stability;108
9.6.4;Reflectance Confocal Microscopy and Stability;109
9.6.5;Biochemical Features and Stability;109
9.6.6;Oxidative Stress and Stability;109
9.6.7;Ultrastructural and Microscopic Features and Stability;110
9.6.8;Immunity and Activity of Vitiligo;110
9.6.9;Stabilization Therapies;112
9.6.10;References;114
10;Section 3 Phototherapy;117
10.1;Chapter 12 Narrow-Band Ultraviolet B Phototherapy in Vitiligo;119
10.1.1;Introduction;119
10.1.2;Light Sources and Lamps;119
10.1.3;Home NB-UVB Phototherapy;119
10.1.4;NB-UVB Administration;120
10.1.5;Contraindications;120
10.1.6;Mechanism of Action of NB-UVB in Vitiligo;121
10.1.7;Efficacy and Prognostic Factors for NB-UVB Monotherapy;121
10.1.8;Persistence of Repigmentation after NB-UVB Treatment;123
10.1.9;Combination Therapy;123
10.1.10;Safety Profile;126
10.1.11;Summary;126
10.1.12;References;126
10.2;Chapter 13 UVA-Based Phototherapy: PUVA, PUVA-Sol, and UVA1 Phototherapy;131
10.2.1;Introduction;131
10.2.2;Psoralen Photochemotherapy (PUVA);131
10.2.3;PUVA?sol;135
10.2.4;UVA1 Phototherapy;136
10.2.5;Other UVA Applications;136
10.2.6;UVA-based Phototherapy in Vitiligo: Conclusions and Future;137
10.2.7;Acknowledgments;137
10.2.8;References;137
10.3;Chapter 14 Targeted Phototherapy in Vitiligo;139
10.3.1;Introduction;139
10.3.2;Targeted Phototherapies in the Treatment of Vitiligo;139
10.3.3;Conclusions;145
10.3.4;References;146
11;Section 4 Medical Management;149
11.1;Chapter 15 Immunomodulators and Immunosuppressives in Vitiligo Treatment;151
11.1.1;Introduction;151
11.1.2;Oral Corticosteroids;151
11.1.3;Narrow-band Ultraviolet B (NB-UVB);152
11.1.4;Ginkgo Biloba;153
11.1.5;Zinc;153
11.1.6;Methotrexate;153
11.1.7;Levamisole;154
11.1.8;Minocycline;154
11.1.9;Statins;154
11.1.10;Tofacitinib Citrate;154
11.1.11;Azathioprine;154
11.1.12;Cyclophosphamide;154
11.1.13;Anti-interferon-gamma Therapeutic Strategy;155
11.1.14;Anti-tumor Necrosis Factor-alpha Treatment (anti-TNF-?);155
11.1.15;References;155
11.2;Chapter 16 Topical Glucocorticoids, Topical Calcineurin Inhibitors, and Topical Vitamin D3 Analogs;159
11.2.1;Introduction;159
11.2.2;Topical Glucocorticoids;159
11.2.3;Topical Calcineurin Inhibitors;160
11.2.4;Topical Vitamin D3 Analogs;163
11.2.5;Conclusions;164
11.2.6;References;164
11.3;Chapter 17 Other Therapies in Vitiligo;167
11.3.1;Introduction;167
11.3.2;Khellin;167
11.3.3;5-Fluorouracil;170
11.3.4;Alpha-lipoic Acid;170
11.3.5;Ginkgo Biloba;170
11.3.6;Pseudocatalase;171
11.3.7;Melagenine;171
11.3.8;Minoxidil;171
11.3.9;Tar;172
11.3.10;Afamelanotide;172
11.3.11;Rituximab;172
11.3.12;Selectively Permeable for NB-UVB Sunscreen;173
11.3.13;Minocycline;173
11.3.14;Bimatoprost;173
11.3.15;Basic Fibroblast Growth Factor (bFGF)-Derived Peptide;173
11.3.16;Piperine;174
11.3.17;References;174
11.4;Chapter 18 Biologic Therapies for Vitiligo;177
11.4.1;Introduction;177
11.4.2;IFN-?-CXCL10-CXCR3 Axis as a Therapeutic Target;177
11.4.3;CXCL10 and CXCL3 Blockers;178
11.4.4;JAK Inhibitors;179
11.4.5;Afamelanotide;181
11.4.6;Conclusions;182
11.4.7;References;182
11.5;Chapter 19 Evidence Toward Integrated Management of Vitiligo, Combining Ayurveda and Homeopathy with Modern Dermatology;185
11.5.1;Introduction;185
11.5.2;Disease Information in Ayurveda;185
11.5.3;Patient Selection in Ayurveda;186
11.5.4;Therapeutics in Ayurveda;187
11.5.5;Dietary Recommendations of IM for Vitiligo;189
11.5.6;Homoeopathic Approach to Treatment;192
11.5.7;References;194
12;Section 5 Surgical Therapies: History, Patient Selection, and Classification;197
12.1;Chapter 20 History and Chronology of Development of Surgical Therapies for Vitiligo;199
12.1.1;Introduction;199
12.1.2;Evolution of Vitiligo as a Physical and Social Disease;200
12.1.3;First Attempts at Vitiligo Grafting: Exchange Grafts;200
12.1.4;The Concept of Stability in Vitiligo;201
12.1.5;The Development of Surgical Methods for Repigmentation of Vitiligo;201
12.1.6;Repigmentation of Leukotrichia;205
12.1.7;Conclusions;205
12.1.8;References;205
12.2;Chapter 21 Patient Selection, Pre- and Postoperative Information in Surgical Therapies for Vitiligo;211
12.2.1;Introduction;211
12.2.2;Patient Selection for Autologous Melanocyte Transplantation;213
12.2.3;Age;215
12.2.4;Contraindications;215
12.2.5;Preoperative Information;215
12.2.6;The Day of Surgery;215
12.2.7;Postoperative Information (Cellular Grafting);216
12.2.8;References;217
12.3;Chapter 22 Classification of Surgical Therapies in Vitiligo;219
12.3.1;Introduction;219
12.3.2;Transplantation of Autologous Melanocytes;219
12.3.3;Tissue Grafts;220
12.3.4;Cellular Grafts;225
12.3.5;Conclusions;230
12.3.6;References;231
13;Section 6 Surgical Therapies: Tissue Grafting;235
13.1;Chapter 23 Minigrafting for Vitiligo;237
13.1.1;Historical perspective;237
13.1.2;The Punch Instrument;237
13.1.3;Evolution of Mini?punch Grafting;238
13.1.4;Test grafting;238
13.1.5;Procedure of minigrafting [32,42-44];239
13.1.6;Follow-up and Course of Events;240
13.1.7;Complications;242
13.1.8;Discussion and Analytical Perspective;242
13.1.9;Conclusions;247
13.1.10;Acknowledgments;247
13.1.11;References;247
13.2;Chapter 24 Suction Blister Epidermal Grafting;251
13.2.1;Introduction;251
13.2.2;Suction blistering;251
13.2.3;Preparation of the Recipient Site;256
13.2.4;Chemical Epilation Before Epidermal Grafting on hair?bearing skin;258
13.2.5;Transfer of grafts and dressing;258
13.2.6;Efficacy and Safety of Epidermal Grafting;259
13.2.7;Advantages and limitations;260
13.2.8;Conclusions;263
13.2.9;References;263
13.3;Chapter 25 Thin and Ultra-Thin Skin Grafts for Vitiligo;267
13.3.1;Introduction;267
13.3.2;History;267
13.3.3;Basic principles and biology of Skin Grafting;267
13.3.4;Selection of patient;268
13.3.5;Methods;268
13.3.6;Conclusions;273
13.3.7;References;273
13.4;Chapter 26 Treatment of Leukoderma by Transplantation of Ultra-Thin Epidermal Sheets Using a Motorized Dermatome;275
13.4.1;Introduction;275
13.4.2;Ultra-thin Epithelial Sheet Grafting Principles;276
13.4.3;Discussion;280
13.4.4;Conclusions;282
13.4.5;References;282
13.5;Chapter 27 Mesh Grafts for Vitiligo;283
13.5.1;Historical background;283
13.5.2;Introduction;283
13.5.3;Technique;284
13.5.4;Conclusions;286
13.5.5;References;286
13.6;Chapter 28 Smash Grafting;287
13.6.1;Introduction;287
13.6.2;Method of Smash Grafting;287
13.6.3;Complications of Smash Grafting;289
13.6.4;Advantages of Smash Grafting;291
13.6.5;Disadvantages;291
13.6.6;References;291
13.7;Chapter 29 Therapeutic Needling and Needling Micrografting;293
13.7.1;Introduction;293
13.7.2;Melanocyte Transplantation in Vitiligo Patients Using Needling Micrografting;293
13.7.3;Results;294
13.7.4;Discussion;296
13.7.5;References;297
13.8;Chapter 30 Complications and Limitations of Melanocyte Transplantation;299
13.8.1;Introduction;299
13.8.2;Complications of Melanocyte Transplantation;299
13.8.3;Limitations of Melanocyte Transplantation;301
13.8.4;Conclusions;302
13.8.5;References;302
14;Section 7 Surgical Therapies: Cellular Grafting;305
14.1;Chapter 31 Treatment of Leukoderma by Transplantation of Basal Cell Layer Suspension;307
14.1.1;Introduction;307
14.1.2;Methods;308
14.1.3;Discussion;314
14.1.4;Conclusions;316
14.1.5;References;316
14.2;Chapter 32 Non-Cultured Extracted Follicle Outer Root Sheath Cell Suspension Transplantation;319
14.2.1;Introduction;319
14.2.2;The role of Hair Follicle Melanocytes and Stem Cells in repigmentation;319
14.2.3;Hair Follicle Transplantation for Vitiligo;320
14.2.4;Transplantation of Hair Follicle Outer Root Sheath Cell Suspension;320
14.2.5;Technique;320
14.2.6;Results reported in Various Studies;322
14.2.7;Advantages;323
14.2.8;Disadvantages;323
14.2.9;Conclusions;323
14.2.10;References;324
14.3;Chapter 33 Long-Term Results of Non-Cultured Epidermal Cellular Grafting in Vitiligo;325
14.3.1;Introduction;325
14.3.2;Long-term results of the non-cultured Epidermal Suspension Technique;325
14.3.3;Conclusions;327
14.3.4;References;327
14.4;Chapter 34 Simplified Non-Cultured Cellular Grafting;329
14.4.1;Introduction;329
14.4.2;Methods;329
14.4.3;Conclusions;334
14.4.4;References;334
14.5;Chapter 35 Novel Methods of Preparing Epidermal Cell Suspension for Transplantation in Vitiligo;335
14.5.1;Introduction;335
14.5.2;Harvesting the Donor Tissue for non-cultured Epidermal Cell Suspension by Dermabrasion;335
14.5.3;Preparation of In?vivo Non?cultured Epidermal Cell Suspension from Suction Blister Graft;338
14.5.4;References;341
14.6;Chapter 36 Management of Vitiligo: Setting Up a Tissue Culture Laboratory;343
14.6.1;Introduction;343
14.6.2;Standards and regulations;343
14.6.3;Laboratory design;343
14.6.4;Equipment;344
14.6.5;Summary;347
14.7;Chapter 37 Treatment of Leukoderma by Transplantation of Cultured Autologous Melanocytes;349
14.7.1;Introduction;349
14.7.2;Methods;351
14.7.3;Discussion;358
14.7.4;Conclusions;359
14.7.5;References;360
14.8;Chapter 38 Transplantation of In-Vitro-Cultured Epithelial Grafts for Vitiligo and Piebaldism;363
14.8.1;Introduction;363
14.8.2;The in-vitro-reconstituted Epidermis-bearing Melanocytes in the Treatment of Pigmentary Disorders;364
14.8.3;The In-vitro-reconstituted Epidermis-bearing Melanocytes: Culture Conditions for Optimal M/K Ratio;364
14.8.4;Clinical Applications of Cultured Epidermis in Pigmentary Disorders;366
14.8.5;Quality Controls of Cell Cultures;366
14.8.6;Selection of Patients;368
14.8.7;Preparation of the Receiving Bed;368
14.8.8;The Importance of Postoperative Management;370
14.8.9;Histologic Examination of the Regenerated Epidermis;370
14.8.10;Overall Success Rate in the Literature;371
14.8.11;Conclusions;371
14.8.12;References;374
14.9;Chapter 39 Application of Lasers for Abrasion in Transplantation Procedures for Vitiligo;377
14.9.1;Introduction;377
14.9.2;Carbon Dioxide Laser;377
14.9.3;Erbium:YAG laser;378
14.9.4;Fractionated CO2 laser;378
14.9.5;Conclusions;379
14.9.6;References;380
14.10;Chapter 40 Cell Delivery on Recipient Skin;383
14.10.1;Introduction;383
14.10.2;Methods and Results;383
14.10.3;Discussion;384
14.10.4;References;386
14.11;Chapter 41 Safety Concerns in Transplantation of In-Vitro-Cultured Cellular Grafts;389
14.11.1;Introduction;389
14.11.2;Regulatory environment;389
14.11.3;Good Manufacturing Practice;390
14.11.4;Cell?culture procedures;391
14.11.5;Quality Assurance System;391
14.11.6;Good Clinical Practice;392
14.11.7;Indian Regulatory Agency;392
14.11.8;References;392
15;Section 8 Special Issues in Medical and Surgical Therapies;395
15.1;Chapter 42 Surgical Management of Vitiligo of Lips, Eyelids, and Genitals;397
15.1.1;Introduction;397
15.1.2;Lips;397
15.1.3;Eyelids;406
15.1.4;Genitals;409
15.1.5;References;411
15.2;Chapter 43 Surgical Management of Acral Vitiligo;415
15.2.1;Introduction;415
15.2.2;When is the Term Acral Vitiligo Used?;415
15.2.3;How is a Surgical Modality Chosen?;417
15.2.4;Preoperative counseling and Informed Consent;418
15.2.5;Preparation of Autologous Melanocyte Cell Suspensions;418
15.2.6;Harvesting of the Skin Graft;419
15.2.7;Modifications of the Procedure For Specific Acral Areas;420
15.2.8;Discussion;424
15.2.9;References;424
15.3;Chapter 44 Surgical Management of Leukotrichia;427
15.3.1;Introduction;427
15.3.2;Treatment of leukotrichia;427
15.3.3;Dermabrasion and ultra?thin split?thickness Skin Grafting;428
15.3.4;Suction Blister Grafting and Systemic PUVA;428
15.3.5;Non-cultured Epidermal Cell Suspension Transplantation;428
15.3.6;Minigrafting;428
15.3.7;Follicular Unit Extraction (FUE) and transplantation;428
15.3.8;Hair transplantation;429
15.3.9;Acknowledgments;430
15.3.10;References;431
15.4;Chapter 45 Surgical Treatments of Leukodermas Other Than Vitiligo Vulgaris;433
15.4.1;Introduction;433
15.4.2;Types of leukoderma and Surgical Methods;433
15.4.3;References;439
15.5;Chapter 46 Ethnic Issues in Management of Vitiligo and Sun Protection;443
15.5.1;Introduction;443
15.5.2;History of vitiligo in Select Cultures;443
15.5.3;Current Social Stigmas About Vitiligo;445
15.5.4;Impact of Cultural Beliefs on treatment and Patient Perceptions of prognosis in vitiligo;447
15.5.5;Sun Protection in Vitiligo Patients: Additional Considerations;448
15.5.6;Conclusions;449
15.5.7;References;449
15.6;Chapter 47 Management Issues for Vitiligo in Children and Pregnant Women;453
15.6.1;Introduction;453
15.6.2;Overview of Issues Pertinent to Pediatric Vitiligo;453
15.6.3;Overview of Issues Pertinent to the Pregnant Vitiligo Patient (see Table 47.2);454
15.6.4;Preventive strategies for vitiligo;455
15.6.5;Issues with General Health in patients with vitiligo;456
15.6.6;Issues with drugs and Other Treatments Used for Vitiligo;456
15.6.7;Conclusions;462
15.6.8;References;462
15.7;Chapter 49 Combination Treatments for Vitiligo;465
15.7.1;Introduction;465
15.7.2;Phototherapy and Medical Treatment;465
15.7.3;Surgery and phototherapy;468
15.7.4;Surgery and Medical Treatment;469
15.7.5;Various combinations of Medical Treatments;470
15.7.6;Conclusions;471
15.7.7;References;473
15.8;Chapter 49 Micropigmentation;477
15.8.1;Introduction;477
15.8.2;Basic principles;477
15.8.3;Pigments and preparations;478
15.8.4;Equipments and procedure;478
15.8.5;Micropigmentation in vitiligo;479
15.8.6;Factors Affecting Cosmetic Results;480
15.8.7;Adverse Effects and Limitations;481
15.8.8;Conclusions;482
15.8.9;References;482
15.9;Chapter 50 Camouflage in Vitiligo;485
15.9.1;Introduction;485
15.9.2;History;485
15.9.3;Basic principles of camouflage;485
15.9.4;Role of camouflage in vitiligo;486
15.9.5;Classification of camouflage;487
15.9.6;Formulations of Cosmetic Camouflage;488
15.9.7;Practical pearls for the application of camouflage;489
15.9.8;Acknowledgments;493
15.9.9;References;493
15.10;Chapter 51 Depigmentation Treatment for Vitiligo: Bleaching Cream, Laser, and Cryotherapy;495
15.10.1;Introduction;495
15.10.2;Depigmentation: The Moment of the decision and indications;495
15.10.3;Depigmentation techniques;496
15.10.4;Comparison Between Laser- and cryotherapy as depigmentation treatment for vitiligo;497
15.10.5;References;498
15.11;Chapter 52 Future Directions in the Treatment of Vitiligo;501
15.11.1;Introduction;501
15.11.2;Stem cells and vitiligo;501
15.11.3;Combating Melanocyte Oxidative Stress;502
15.11.4;Tackling autoimmunity;502
15.11.5;Stimulating melanocytes;505
15.11.6;Advances in Surgical Treatment;507
15.11.7;Maintaining repigmentation in Vitiligo Patches;507
15.11.8;Biomarkers to Predict Disease Activity and stability in vitiligo;508
15.11.9;Conclusions;510
15.11.10;References;510
15.12;Chapter 53 Informed Consent;517
15.12.1;Introduction/background;517
15.12.2;Clinical studies;517
15.12.3;Layout of the form;519
15.12.4;References;519
16;Index;521
17;EULA;536mehr

Autor